Rainier Acquisition Corporation, a special purpose acquisition company focused on global life sciences sectors including therapeutics and diagnostics, priced a $75 million initial public offering on the Nasdaq Capital Market.
The IPO consists of 7.5 million units at $10 each, with each unit comprising one Class A ordinary share and one-quarter of a redeemable warrant. The underwriting syndicate, led by Chardan as sole book-running manager, retains a 45-day option to purchase up to an additional 1.125 million units at the offering price.
Units are expected to begin trading under the ticker "RNAQU" on August 27, 2026, one day after the SEC declared the registration statement effective. Following unit separation, the Class A ordinary shares will trade as "RNAQ" and the warrants as "RNAQW" on the Nasdaq Capital Market.
The company, led by CEO Gbola Amusa and CFO Guy Barudin, targets investments in life sciences industries including genomics, precision medicine, and biomanufacturing. The offering is slated to close on August 28, 2026.
